Bi-allelic mutations of DDR-associated genes, such as ATM, BRCA2, PALB2, RB1, and TP53, are not only drivers of tumor evolution in cancers, but are also significantly associated with the responses to various treatment modalities, including PARP inhibitors and immunotherapies [31]. This evidence concerns the gene RB1 and cancer.